Key Highlights

  • Alumis announced that its Phase 2b LUMUS trial of envudeucitinib for moderate-to-severe SLE failed to meet its primary and secondary endpoints.
  • The miss occurred across the general participant population.
  • The company highlighted dose-dependent interferon engagement and favorable responses in a prespecified IFNGS-high subgroup.
  • Alumis maintains its Q4 2026 timeline for a psoriasis NDA submission.

Alumis Inc. (NASDAQ: ALMS) announced that its Phase 2b LUMUS trial of envudeucitinib for moderate-to-severe systemic lupus erythematosus failed to meet its primary and secondary endpoints across the general participant population.

What Happened

Despite the miss, the company highlighted dose-dependent interferon engagement and favorable responses in a prespecified IFNGS-high subgroup to support future Phase 3 regulatory dialogues, while maintaining its Q4 2026 timeline for a psoriasis NDA submission.

Market Reaction

The disclosed information does not include stock price or trading data for Alumis following the trial results.

Outlook

Future regulatory dialogues regarding a potential Phase 3 path in the IFNGS-high subgroup, alongside the planned Q4 2026 psoriasis NDA submission, represent the next disclosed milestones for Alumis.